KR20160054570A - 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 - Google Patents

통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 Download PDF

Info

Publication number
KR20160054570A
KR20160054570A KR1020167009294A KR20167009294A KR20160054570A KR 20160054570 A KR20160054570 A KR 20160054570A KR 1020167009294 A KR1020167009294 A KR 1020167009294A KR 20167009294 A KR20167009294 A KR 20167009294A KR 20160054570 A KR20160054570 A KR 20160054570A
Authority
KR
South Korea
Prior art keywords
compound
pain
chloro
compounds
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167009294A
Other languages
English (en)
Korean (ko)
Inventor
올가 바비크
티나 게리안테스
로버츠 제트. 루오
데이비드 제이. 폴링
스리니바산 피. 벤카타찰란
야닐린 왕-피셔
Original Assignee
크로모셀 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크로모셀 코포레이션 filed Critical 크로모셀 코포레이션
Publication of KR20160054570A publication Critical patent/KR20160054570A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR1020167009294A 2013-09-10 2014-09-09 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 Ceased KR20160054570A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361876046P 2013-09-10 2013-09-10
US61/876,046 2013-09-10
PCT/US2014/054764 WO2015038533A2 (en) 2013-09-10 2014-09-09 Sodium channel modulators for the treatment of pain and diabetes

Publications (1)

Publication Number Publication Date
KR20160054570A true KR20160054570A (ko) 2016-05-16

Family

ID=52666496

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167009294A Ceased KR20160054570A (ko) 2013-09-10 2014-09-09 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자

Country Status (18)

Country Link
US (2) US20160221974A1 (enExample)
EP (1) EP3043787B1 (enExample)
JP (1) JP6445565B2 (enExample)
KR (1) KR20160054570A (enExample)
CN (1) CN105611923B (enExample)
AU (1) AU2014318979B2 (enExample)
BR (1) BR112016005271A2 (enExample)
CA (1) CA2922851C (enExample)
ES (1) ES2687598T3 (enExample)
IL (1) IL244506B (enExample)
MX (1) MX2016002881A (enExample)
MY (1) MY181928A (enExample)
PH (1) PH12016500296A1 (enExample)
RU (1) RU2016113156A (enExample)
SG (2) SG10201805552PA (enExample)
UA (1) UA120353C2 (enExample)
WO (1) WO2015038533A2 (enExample)
ZA (1) ZA201702410B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179781B2 (en) * 2013-03-15 2019-01-15 Chromocell Corporation Sodium channel modulators for the treatment of pain
CN105611923B (zh) 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂
EP3193610A4 (en) * 2014-09-09 2018-04-04 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes
CN108699015A (zh) 2015-12-18 2018-10-23 默沙东公司 对电压门控性钠通道具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代的二胺-芳基磺胺化合物
WO2017201468A1 (en) 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN105924670A (zh) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 一种电力电缆用耐磨剂
CN105924843A (zh) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 一种耐刮擦的电力电缆
CN106084535A (zh) * 2016-06-02 2016-11-09 扬州兰都塑料科技有限公司 一种耐刮擦的电力电缆的制备方法
EP3551626B1 (en) 2016-12-09 2023-10-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN106892845B (zh) * 2017-02-28 2018-10-30 四川同晟生物医药有限公司 一种2,4-二氨基丁酸衍生物及其制备方法
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
AU2019285184B2 (en) 2018-06-13 2023-11-16 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用
WO2026090267A1 (en) * 2024-10-23 2026-04-30 Pelthos Therapeutics Inc. Ophthalmic formulations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
PT1368355E (pt) * 2001-03-14 2006-09-29 Gruenenthal Gmbh Pirazolopirimidinas e tiazolopirimidinas substituidas, como analgesicos
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
EP1689719A1 (en) 2003-11-25 2006-08-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2006011050A2 (en) * 2004-07-23 2006-02-02 Pfizer Limited Pyridine derivatives
WO2006046916A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
US7622496B2 (en) * 2005-12-23 2009-11-24 Zealand Pharma A/S Modified lysine-mimetic compounds
CA2677493A1 (en) * 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
US8853250B2 (en) 2007-07-13 2014-10-07 Icagen, Inc. Sodium channel inhibitors
CA2747419C (en) * 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
EP2560636A4 (en) 2010-04-23 2013-11-27 Kineta Inc ANTIVIRAL CONNECTIONS
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
ES2526675T3 (es) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
EP2593427B1 (en) 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
WO2012099983A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
UY34171A (es) * 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
AU2012296529A1 (en) 2011-08-17 2014-02-20 Amgen Inc. Heteroaryl sodium channel inhibitors
WO2013043925A1 (en) * 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
US9757379B2 (en) 2012-11-14 2017-09-12 The Board Of Regents Of The University Of Texas System Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
US10179781B2 (en) * 2013-03-15 2019-01-15 Chromocell Corporation Sodium channel modulators for the treatment of pain
EP3417851B1 (en) 2013-09-09 2020-07-22 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
CN105611923B (zh) 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂
EP3193610A4 (en) 2014-09-09 2018-04-04 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes

Also Published As

Publication number Publication date
AU2014318979B2 (en) 2019-03-28
CA2922851C (en) 2023-03-14
RU2016113156A (ru) 2017-10-16
ES2687598T3 (es) 2018-10-26
CN105611923B (zh) 2019-08-23
CA2922851A1 (en) 2015-03-19
EP3043787A4 (en) 2017-02-01
CN105611923A (zh) 2016-05-25
US20160221974A1 (en) 2016-08-04
RU2016113156A3 (enExample) 2018-07-02
WO2015038533A3 (en) 2015-10-29
EP3043787B1 (en) 2018-09-05
US9458118B2 (en) 2016-10-04
UA120353C2 (uk) 2019-11-25
PH12016500296A1 (en) 2016-05-16
US20160130239A1 (en) 2016-05-12
SG10201805552PA (en) 2018-08-30
SG11201601367QA (en) 2016-03-30
IL244506A0 (en) 2016-04-21
JP6445565B2 (ja) 2018-12-26
BR112016005271A2 (pt) 2020-05-12
MY181928A (en) 2021-01-14
AU2014318979A1 (en) 2016-03-03
ZA201702410B (en) 2019-06-26
WO2015038533A2 (en) 2015-03-19
JP2016532716A (ja) 2016-10-20
EP3043787A2 (en) 2016-07-20
MX2016002881A (es) 2016-04-21
IL244506B (en) 2020-02-27

Similar Documents

Publication Publication Date Title
EP3043787B1 (en) Sodium channel modulators for the treatment of pain and diabetes
US10179781B2 (en) Sodium channel modulators for the treatment of pain
TW201040186A (en) Phthalazine-containing antidiabetic compounds
TW200946524A (en) Certain chemical entities, compositions and methods
JP6754828B2 (ja) ピリジン及びピリミジン誘導体
US20170304306A1 (en) SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES
TW202330472A (zh) 化合物、組合物及使用方法
CA3088968C (en) Dihydroindolizinone derivative
JP7527039B2 (ja) Ｇｌｕｔ１欠損症症候群の治療に使用するためのイソキノリン誘導体
HK1224572A1 (en) Sodium channel modulators for the treatment of pain and diabetes
CN112745319A (zh) 一类取代三环结构的化合物、其制备方法及用途
WO2008067713A1 (fr) Composés à structure de cyclopentane, leurs procédés de préparation et leurs utilisations médicales
US20220280644A1 (en) "TRPswitch" - A STEP FUNCTION CHEMO-OPTOGENETIC LIGAND

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160408

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190909

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210604

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211118

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210604

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I